Orbis Medicines and Novo Nordisk announced a multi-target drug discovery partnership worth up to US$1.4 billion, aimed at turning injectable biologics into orally dosed macrocycle medicines for cardiometabolic disease. The deal, disclosed September 17, is one of the largest AI-native biotech collaborations announced this year.
What Novo Is Buying
The headline number stacks an undisclosed upfront payment against development and commercial milestones and tiered royalties on future product sales. Novo will also make a direct strategic equity investment in Orbis, tightening the alignment beyond a straight fee-for-service discovery deal.
At the centre of the contract is Orbis's nGen platform — a generative AI drug discovery engine trained on datasets from the company's high-throughput macrocycle chemistry and screening operation. nGen designs orally bioavailable macrocycles, which Orbis brands as nCycles, using a multi-parameter optimisation loop that co-optimises target affinity, permeability, metabolic stability and manufacturability.
Oral Biologics As The New Battleground
The commercial thesis is straightforward: many of the highest-value biological targets — GLP-1 receptors, incretin analogues, cytokine pathways — are currently addressed with injections. Convert them into a pill and adherence, cost of goods and patient reach jump in a single step. That is the same wager driving Novo's parallel AI collaboration with Anthropic on Claude Science, announced only a day earlier.
"This collaboration reinforces that the future of oral biologic drug discovery lies at the intersection of AI, proprietary experimental macrocycle datasets and world-class automated chemistry," said Orbis CEO Morten Graugaard. Novo Nordisk's senior vice president of therapeutics discovery Brian Vandahl added that the collaboration "has the potential to unlock innovative oral treatment options for patients with cardiometabolic diseases."
What It Signals For AI-Native Biotech
Orbis, spun out of Novo Holdings's seed portfolio and headquartered in Copenhagen with a chemistry hub in Lausanne, sits alongside a wave of AI-driven biotech partnerships where the AI platform, not the pipeline, is the primary asset. Investors have already priced that thesis into rounds such as Anew Labs's $290M round at a $1.5B valuation. Novo's cheque is a validation that the world's largest metabolic-disease franchise is willing to underwrite that thesis at scale.
Reporting based on Orbis Medicines's press release via BioSpace and Business Wire (September 17, 2026).